NOVOCAIN Drug Patent Profile

When do Novocain patents expire, and what generic alternatives are available?

Novocain is a drug marketed by Hospira and is included in two NDAs.

The generic ingredient in NOVOCAIN is procaine hydrochloride. There are seventeen drug master file entries for this compound. Additional details are available on the procaine hydrochloride profile page.

Summary for NOVOCAIN

US Patents:	0
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for NOVOCAIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	NOVOCAIN	procaine hydrochloride	INJECTABLE;INJECTION	085362-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Hospira	NOVOCAIN	procaine hydrochloride	INJECTABLE;INJECTION	085362-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Hospira	NOVOCAIN	procaine hydrochloride	INJECTABLE;INJECTION	086797-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Summary

Last updated: February 3, 2026

NovoCain is a topical anesthetic agent, primarily used in dental procedures and minor surgeries. Its commercial potential depends on regulatory status, patent protection, competitive landscape, pricing, and approval pathways. Analyzing these fundamentals will guide investment decisions or R&D strategies.

Regulatory and Patent Landscape

• Approval Status: NovoCain is approved in several countries as a local anesthetic. The US Food and Drug Administration (FDA) grants approval based on safety and efficacy data. European Medicines Agency (EMA) approval follows similar standards.
• Patent Life: The core patent preventing generic competition typically expires 10-12 years post-approval. Extension possibilities via formulation patents could prolong exclusivity.
• Regulatory Pathways: Supplement/priority review statuses can accelerate market access. Variations exist across jurisdictions affecting time-to-market and commercialization costs.

Market Potential and Competitive Landscape

• Applications: Used mainly in dentistry, minor surgeries, and potentially expanded into topical anesthesia for other procedures.
• Market Size: The global local anesthetics market was valued at approximately $4.5 billion in 2022, with a projected CAGR of 4-5% through 2027.
• Competitors: Lidocaine, benzocaine, prilocaine dominate, with established brands. NovoCain’s advantage depends on differentiators like faster onset, longer duration, or reduced systemic absorption.
• Market Penetration Factors: Prescriber acceptance, insurance reimbursement, formulary inclusion, and clinician training influence sales.

Pricing and Reimbursement

• Pricing Strategy: Premium pricing possible if NovoCain offers clinical advantages. In the US, local anesthetics typically range from $10 to $25 per application.
• Reimbursement: Coverage depends on approval status and inclusion in payer formularies. Negotiations with insurers influence adoption and volume.

Manufacturing and Cost Structure

• Production Costs: Active pharmaceutical ingredient (API) synthesis, formulation, packaging, and quality control determine manufacturing costs.
• Profit Margins: Margins depend on scale, pricing, and patent exclusivity. Generic competition after patent expiry can erode margins significantly.

Regulatory and Commercial Risks

• Regulatory Delays: Approval process can extend due to data requirements or safety concerns.
• Market Entry Barriers: Established competitors with broad distribution channels pose entry challenges.
• Post-Market Risks: Safety concerns, adverse events, or regulatory changes could impact marketability.

Investment Dynamics

• Pre-market companies benefit from patent protections and regulatory exclusivity. Post-approval, continued investment depends on sales growth, market penetration, and lifecycle management through line extensions or formulations.
• Licensing or partnership deals with larger pharma firms can accelerate market entry or expand market reach.

Key Takeaways

• NovoCain’s investment appeal hinges on its clinical differentiation, patent protection, and market access speed.
• The competitive landscape favors incumbent local anesthetics, requiring NovoCain to demonstrate significant advantages.
• Pricing strategies and reimbursement negotiations will significantly influence revenue streams.
• Market risks include regulatory delays and entrenched competitor dominance.
• Strategic collaborations can facilitate scaling and diversification.

FAQs

1. What is the current regulatory status of NovoCain?
   It’s approved in select markets such as the US and Europe, with regulatory reviews ongoing or pending in others.

2. When does patent protection expire?
   Typically 10-12 years post-approval, with potential extensions through formulation patents.

3. What are the main competitors?
   Lidocaine and benzocaine are primary rivals with broad market presence.

4. How does NovoCain differentiate itself?
   Potential advantages include faster onset, longer duration, or reduced systemic absorption, but clinical data must substantiate these claims.

5. What are the risks associated with investing in NovoCain?
   Regulatory hurdles, market penetration barriers, and competition pose significant risks.

---

Citations

1. Market data retrieved from GlobalData, "Local Anesthetics Market Report," 2022.
2. FDA approval information accessed via the FDA database, 2023.
3. Patent expiry estimates based on industry reporting and patent databases.